OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Logan on the Integration of Obe-Cel into Relapsed/Refractory ALL Management

August 7th 2025

Aaron C. Logan, MD, PhD, discusses the FDA approval of the obe-cel in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Dr Florez on First-Line Treatment Factors in EGFR+ NSCLC

August 7th 2025

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.

Dr Florez Highlights Real-Time Polling Results on Treatment Preferences in SCLC

August 7th 2025

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the 2025 Bridging the Gaps in Lung Cancer meeting.

Dr Malhotra on the Future of Sigvotatug Vedotin in NSCLC

August 7th 2025

Jyoti Malhotra, MD, MPH, discusses future research directions for sigvotatug vedotin in non–small cell lung cancer.

Dr Mehnert on the Rationale for Adding IL-6 Blockade to Checkpoint Inhibition in Melanoma

August 7th 2025

Janice Mehnert, MD, discusses the rationale for incorporating IL-6 receptor blockade into a combination with checkpoint inhibition for patients with advanced melanoma.

Dr Eng on the Future Role for Targeted Therapy in mCRC

August 7th 2025

Cathy Eng, MD, FACP, FASCO, discusses efforts to shift emerging targeted therapies into earlier treatment lines for patients with mCRC.

Dr Cloughesy on the FDA Approval of Dordaviprone for Diffuse Midline Glioma

August 6th 2025

Timothy F. Cloughesy, MD, discusses the FDA approval of dordaviprone for the treatment of patients with H3K27M-mutated diffuse midline glioma.

Dr García-Carbonero on Considerations for Poorly Differentiated GI Neuroendocrine Carcinoma

August 6th 2025

Rocío García-Carbonero, MD, outlines diagnostic and molecular considerations for poorly differentiated GI neuroendocrine carcinoma.

Dr Olawaiye on Next Steps for Investigating Relacorilant in Platinum-Resistant Ovarian Cancer

August 6th 2025

Alexander B. Olawaiye, MD, discusses future research directions with relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

Dr Popat on JNJ-5322 in Relapsed/Refractory Multiple Myeloma

August 5th 2025

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, discusses data with the trispecific antibody JNJ-5322 in relapsed/refractory multiple myeloma.

Dr Cascone on Perioperative Nivolumab in Resectable NSCLC

August 5th 2025

Tina Cascone, MD, PhD, discusses of perioperative nivolumab vs placebo in patients with resectable non–small cell lung cancer.

Dr Dorritie on the Role of Quadruplet Regimens in Multiple Myeloma

August 5th 2025

Kathleen A. Dorritie, MD, discusses the role of quadruplet regimens for the treatment of patients with multiple myeloma.

Dr Wong on Survival Outcomes and Molecular Characteristics of Patients with Early-Onset CRC

August 5th 2025

Evelyn Y.T. Wong, MD, discusses survival outcomes and molecular characteristics of patients with early-onset colorectal cancer from a cohort in Singapore.

Dr Kudo on Evaluating Nivolumab/Ipilimumab in Unresectable HCC

August 5th 2025

Masatoshi Kudo, MD, PhD, discusses a MAIC evaluating nivolumab/ipilimumab vs durvalumab/tremelimumab and atezolizumab/bevacizumab for unresectable HCC.

Dr Haas on Evolutions in Clinical Trial Design in the RCC Treatment Paradigm

August 4th 2025

Naomi B. Haas, MD, discusses previously conducted trials that supported the initiation of the KEYNOTE-564 trial of adjuvant pembrolizumab in RCC.

Dr George on the Clinical Relevance of Targetable Mutations in GIST

August 4th 2025

Suzanne George, MD, discusses the evolving development of targeted therapies for patients with gastrointestinal stromal tumor.

Dr McKay on the Role of Casdatifan Plus Cabozantinib in Clear Cell RCC

August 4th 2025

Rana R. McKay, MD, FASCO, details the significance of casdatifan plus cabozantinib demonstrating better responses vs the respective agents alone in ccRCC.

Dr Maese on Asparaginase-Based Regimens in Adult/Young Adult ALL

August 4th 2025

Luke Maese, DO, discusses treatment considerations for asparaginase-containing regimens in adult and young adult patients with ALL.

Dr Shah on Outcomes With Checkpoint Inhibition in Patients With Cancer and Pre-Existing Neurologic Autoimmune Disorders

August 4th 2025

Shailee S. Shah, MD, shares data on the frequency and severity of NAID exacerbation with ICIs in patients with cancer.

Dr Tan on the Ongoing Investigation of Adaptive Treatment Intensification Strategies in RCC

August 1st 2025

Alan Tan, MD, discusses current and future avenues for evaluating adaptive immunotherapy approaches in treatment-naive metastatic RCC.